Last reviewed 2026-05-21 · How we verify

Pathogen-Reduced Platelet Concentrates

Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen · Phase 2 active Biologic ✓ Verified May 2026

Pathogen-Reduced Platelet Concentrates is a Biologic drug developed by Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen. It is currently in Phase 2 development.

Pathogen-Reduced Platelet Concentrates are used to treat conditions such as thrombocytopenia and aplasia with expected thrombocytopenia, as well as platelet transfusion. They are a type of platelet concentrate, also known as platelet concentrate, which is used in medical treatment.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Pathogen-Reduced Platelet Concentrates
Sponsor	Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pathogen-Reduced Platelet Concentrates CI brief — competitive landscape report
Pathogen-Reduced Platelet Concentrates updates RSS · CI watch RSS
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen portfolio CI

Frequently asked questions about Pathogen-Reduced Platelet Concentrates

What is Pathogen-Reduced Platelet Concentrates?

Pathogen-Reduced Platelet Concentrates is a Biologic drug developed by Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen.

Who makes Pathogen-Reduced Platelet Concentrates?

Pathogen-Reduced Platelet Concentrates is developed by Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen (see full Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen pipeline at /company/deutsches-rotes-kreuz-drk-blutspendedienst-baden-wurttemberg-hessen).

What development phase is Pathogen-Reduced Platelet Concentrates in?

Pathogen-Reduced Platelet Concentrates is in Phase 2.

Manufacturer: Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing